The Current Ratio as of December 2024 (TTM) for Genelux Corporation (GNLX) is 6.47

According to Genelux Corporation’s latest financial reports and current stock price. The company's current Current Ratio is 6.47. This represents a change of 37.08% compared to the average of 4.72 of the last 4 quarters.

Genelux Corporation (GNLX) Historical Current Ratio (quarterly & annually)

How has GNLX Current Ratio performed in the past?

The mean historical Current Ratio of Genelux Corporation over the last ten years is 0.97. The current 6.47 Current Ratio has changed 66.77% with respect to the historical average. Over the past ten years (40 quarters), GNLX's Current Ratio was at its highest in in the September 2024 quarter at 6.47. The Current Ratio was at its lowest in in the December 2022 quarter at 0.06.

Genelux Corporation (GNLX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Genelux Corporation Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Genelux Corporation (GNLX) Average Current Ratio

How has GNLX Current Ratio performed in the past?

The current Current Ratio of Genelux Corporation (GNLX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Genelux Corporation (GNLX) Current Ratio vs. Peers

How is GNLX’s Current Ratio compared to its peers?

Genelux Corporation’s Current Ratio is greater than Comera Life Sciences Holdings, Inc. (0.90), greater than Dyadic International, Inc. (5.15), less than Cingulate Inc. (7.35), greater than Monopar Therapeutics Inc. (5.41), less than Terns Pharmaceuticals, Inc. (32.99), less than Day One Biopharmaceuticals, Inc. (14.62), less than Acumen Pharmaceuticals, Inc. (10.43), greater than Amylyx Pharmaceuticals, Inc. (4.55), less than MoonLake Immunotherapeutics (25.51), greater than Monte Rosa Therapeutics, Inc. (6.03), less than NewAmsterdam Pharma Company N.V. (10.61), greater than Inventiva S.A. (0.96), less than Cullinan Oncology, Inc. (24.46), less than Compass Therapeutics, Inc. (31.84), less than Larimar Therapeutics, Inc. (13.10), less than Immuneering Corporation (7.99), less than Centessa Pharmaceuticals plc (21.52), less than Celcuity Inc. (10.36), less than Ikena Oncology, Inc. (15.32),

Build a custom stock screener for Genelux Corporation (GNLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genelux Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genelux Corporation (GNLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genelux Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.